Adult Dosing
Treatment of thrombocythemia associated with myeloproliferative disorders
- Initial: 0.5 mg PO qid or 1 mg PO bid
- Titrate: Increase 0.5 mg/day qwk
- Max: 10 mg/day; 2.5 mg/dose
- Note: Use lowest effective dose to maintain platelet count < 600000
Pediatric Dosing
Treatment of thrombocythemia associated with myeloproliferative disorders
7-14 yrs
- Initial: 0.5 mg PO qd
- Titrate: Increase 0.5 mg/day qwk
- Max: 10 mg/day; 2.5 mg/dose
- Note: Limited data available in pediatric population. Use lowest effective dose to maintain platelet count < 600000
[Outline]
- Thrombocythemia associated with myeloproliferative disorders, to reduce elevated platelet count and risk of thrombosis events, and to relieve associated symptoms, including thrombohemorrhagic events
Note: Typically, platelet count begins to respond within 7 to 14 days at the proper dosage
- Anagrelide may cause vasodilation, tachycardia, palpitations, and heart failure. Assess cardiovascular status before initiation of therapy and periodically during therapy
- Cessation of therapy may cause platelet count to rise within 4 days. To prevent the occurrence of thrombocytopenia, perform platelet counts q2 days during 1st wk and at least weekly thereafter until maintenance dose is reached
- Assess benefit/risk in patients with mild and moderate impairment of hepatic function before starting treatment
- Carefully monitor the patients with moderate hepatic impairment for cardiovascular effects and adjust the dose appropriately
- Monitor CBC, serum creatinine and BUN
- Monitor LFTs before at baseline and periodically thereafter
- Closely monitor the patients with known or suspected heart disease, renal insufficiency and hepatic dysfunction
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment (refer dosing adjustment section)
- Cardiovascular disease
- Changes in smoking habits
Pregnancy Category:C
Breastfeeding: Safety unknown. Manufacturer recommends discontinuation of breastfeeding, or discontinuation of treatment (taking into account the importance of the drug to the mother).
Pricing data from www.DrugStore.com in U.S.A.
- Agrylin 1 MG CAPS [Bottle] (SHIRE US INC.)
50 mg = $545.99
150 mg = $1621.95 - Agrylin 0.5 MG CAPS [Bottle] (SHIRE US INC.)
50 mg = $359.99
150 mg = $996.01 - Anagrelide HCl 0.5 MG CAPS [Bottle] (IVAX PHARMACEUTICALS)
INC. mg = $30
mg = $90 - Anagrelide HCl 1 MG CAPS [Bottle] (IVAX PHARMACEUTICALS)
INC. mg = $50
mg = $150
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.